NasdaqCM:FBRXBiotechs
Is Forte Biosciences (FBRX) Fully Valued Following Its Positive FB102 Vitiligo Data?
Forte Biosciences (FBRX) is back in focus after reporting statistically significant phase 1b data for FB102 in vitiligo, with early and sustained FVASI improvements and a safety profile that compared favorably to placebo.
See our latest analysis for Forte Biosciences.
Forte Biosciences has seen sharp positive momentum build around these FB102 results, with the 1 month share price return of 173.73% and year to date share price return of 106.95% contributing to a very large 1 year total...